Vanda Pharmaceuticals’ (VNDA) Buy Rating Reaffirmed at B. Riley Financial

Posted by Brian Himes on Aug 10th, 2026

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report)‘s stock had its “buy” rating reaffirmed by investment analysts at B. Riley Financial in a research report issued on Monday,Benzinga reports. They presently have a $12.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $17.00. B. Riley Financial’s price objective indicates a potential upside of 144.65% from the company’s previous close.

Several other research analysts also recently commented on VNDA. HC Wainwright dropped their price target on Vanda Pharmaceuticals from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Monday. Wall Street Zen cut Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $13.70.

View Our Latest Analysis on Vanda Pharmaceuticals

Vanda Pharmaceuticals Stock Down 1.9%

Shares of NASDAQ:VNDA traded down $0.10 on Monday, reaching $4.91. The company had a trading volume of 877,616 shares, compared to its average volume of 1,679,127. The stock has a market capitalization of $294.96 million, a P/E ratio of -1.06 and a beta of 0.64. The stock has a 50-day moving average price of $5.78 and a 200 day moving average price of $6.75. Vanda Pharmaceuticals has a twelve month low of $4.15 and a twelve month high of $9.94. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The company had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. On average, equities analysts expect that Vanda Pharmaceuticals will post -2.2 EPS for the current year.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Torren Management LLC bought a new stake in shares of Vanda Pharmaceuticals during the fourth quarter valued at approximately $25,000. Russell Investments Group Ltd. raised its position in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares during the last quarter. Quarry LP acquired a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $53,000. Cerity Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter valued at $69,000. Finally, Boothbay Fund Management LLC bought a new position in Vanda Pharmaceuticals in the third quarter valued at about $72,000. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

(Get Free Report)

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.